{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:09:17Z","timestamp":1747224557100,"version":"3.40.5"},"reference-count":12,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Monaldi Arch Chest Dis"],"abstract":"<jats:p>Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.<\/jats:p>","DOI":"10.4081\/monaldi.2022.2388","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:16:57Z","timestamp":1663665417000},"source":"Crossref","is-referenced-by-count":0,"title":["Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report"],"prefix":"10.4081","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-7744","authenticated-orcid":false,"given":"Cristiano","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Caterino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-7037","authenticated-orcid":false,"given":"Fabio","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cotroneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5002-0128","authenticated-orcid":false,"given":"Roberta","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Zamparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"21039","doi-asserted-by":"crossref","unstructured":"Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20:654-9.","DOI":"10.1111\/resp.12496"},{"key":"21040","doi-asserted-by":"crossref","unstructured":"Comella P, Frasci G, De Cataldis G, et al. Cisplatin\/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996;74:1805-11.","DOI":"10.1038\/bjc.1996.634"},{"key":"21041","unstructured":"Cattaneo F, Guerra G, Parisi M, et al. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res 2015;35:2769-74."},{"key":"21042","doi-asserted-by":"crossref","unstructured":"Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci 2019;20:4931.","DOI":"10.3390\/ijms20194931"},{"key":"21043","doi-asserted-by":"crossref","unstructured":"Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients. Int J Mol Sci 2019;20:2258.","DOI":"10.3390\/ijms20092258"},{"key":"21044","doi-asserted-by":"crossref","unstructured":"Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453.","DOI":"10.1002\/14651858.CD013453.pub2"},{"key":"21045","doi-asserted-by":"crossref","unstructured":"Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018;17:52.","DOI":"10.1186\/s12943-018-0810-4"},{"key":"21046","doi-asserted-by":"crossref","unstructured":"Moore DA, Benafif S, Poskitt B, et al. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer 2021;161:55-9.","DOI":"10.1016\/j.lungcan.2021.08.008"},{"key":"21047","doi-asserted-by":"crossref","unstructured":"Doxtader EE, Cheng YW, Zhang Y. Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration: The Cleveland clinic experience. Arch Pathol Lab Med 2019;143:670-6.","DOI":"10.5858\/arpa.2017-0184-RA"},{"key":"21048","doi-asserted-by":"crossref","unstructured":"Perrotta F, Nankivell M, Adizie JB, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 2020;158:1230-9.","DOI":"10.1016\/j.chest.2020.04.059"},{"key":"21049","doi-asserted-by":"crossref","unstructured":"Ando K, Akimoto K, Sato H, et al. Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis. Cancers (Basel) 2020;12:942.","DOI":"10.3390\/cancers12040942"},{"key":"21050","doi-asserted-by":"crossref","unstructured":"Serritella AV, Bestvina CM. Anaplastic lymphoma kinase mutation-positive non-small cell lung cancer. Thorac Surg Clin 2020;30:137-46.","DOI":"10.1016\/j.thorsurg.2019.12.001"}],"container-title":["Monaldi Archives for Chest Disease"],"original-title":[],"link":[{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/download\/2388\/1515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/download\/2388\/1515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:17:37Z","timestamp":1663665457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/view\/2388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.4081\/monaldi.2022.2388","relation":{},"ISSN":["2532-5264","1122-0643"],"issn-type":[{"type":"electronic","value":"2532-5264"},{"type":"print","value":"1122-0643"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}